Cited by 2,663Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processesHematopoietic Stem Cell Transplantation

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Open access

Fenaux, Pierre, Mufti, Ghulam J, Hellstrom-Lindberg, Eva, Santini, Valeria, Finelli, Carlo, Giagounidis, Aristoteles, Schoch, Robert, Gattermann, Norbert, Sanz, Guillermo, List, Alan, Gore, Steven D, Seymour, John F, Bennett, John M, Byrd, John, Backstrom, Jay, Zimmerman, Linda, McKenzie, David, Beach, CL, Silverman, Lewis R·2009·The Lancet Oncology

DOI 10.1016/s1470-2045(09)70003-8PMC PMC4086808

Open this paper in CoChat — free account

Abstract

Background Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens.Methods In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m(2) per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation). Patients were stratified by French-American-British and international prognostic scoring system classifications; randomisation was done with a block size of four. The primary endpoint was overall survival. Efficacy analyses were by intention to treat for all patients assigned to receive treatment. This study is registered with ClinicalTrials.gov, number NCT00071799.Findings Between Feb 13, 2004, and Aug 7, 2006, 358 patients were randomly assigned to receive azacitidine (n=179) or conventional care regimens (n=179). Four patients in the azacitidine and 14 in the conventional care groups received no study drugs but were included in the intention-to-treat efficacy analysis. After a median follow-up of 21.1 months (IQR 15.1-26.9), median overall survival was 24.5 months (9.9-not reached) for the azacitidine group versus 15.0 months (5.6-24.1) for the conventional care group (hazard ratio 0.58; 95% CI 0.43-0.77; stratified log-rank p=0.0001). At last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. At 2 years, on the basis of Kaplan-Meier estimates, 50.8% (95% CI 42.1-58.8) of patients in the azacitidine group were alive compared with 26.2% (18.7-34.3) in the conventional care group (p<0.0001). Peripheral cytopenias were the most common grade 3-4 adverse events for all treatments.Interpretation Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(09)70003-8

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citation
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619
Self-citation
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Müller‐Hermelink, H. K., Vardiman, J. W., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,261
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Döhner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,686
Self-citation
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310

Show all 45 references

Sorted by citations

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Döhner, H., Estey, E. H., Grimwade, D. J., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,900
Self-citation
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citation
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Myelodysplastic Syndromes
Greenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Borate, U., Castro, C. M. D., Deeg, H. J., Frankfurt, O., Gaensler, K. M. L., Garcia-Manero, G., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0104 · Cited by 1,625
Self-citation
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,611
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Kantarjian, H. M., Thomas, X., Dmoszyńska, A., Wierzbowska, A., Mazur, G. J., Mayer, J., Gau, J., Chou, W., Buckstein, R. J., Čermák, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,170
“A retrospective subanalysis of data from a phase III trial in patients with MDS evaluated survival with azacitidine (n 55) versus conventional care (best SC, low-dose cytarabine, or intensive chemotherapy; n 58).(16,17) The study population, which was originally classified as having refractory anemia with excess blast…”
Method
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Self-citation
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J. J., & Baylin, S. B. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,153
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Self-citation
Epigenetic modifications as therapeutic targets
Kelly, T. K., Carvalho, D. D. D., & Jones, P. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1678 · Cited by 822
“5-Azacytidine (5-Aza-CR; Vidaza; azacitidine), a nucleoside analog that is incorporated into RNA and DNA, is approved to treat patients with high-risk myelodysplastic syndromes (MDS) and successful clinical results have recently been reported ( Tables 2 and 3”
Background
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer
Juergens, R. A., Wrangle, J. M., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N. C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Sperling, A. S., Gibson, C. J., & Ebert, B. L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.112 · Cited by 695
“Both drugs are active in MDS, and 5-azacitidine improves overall survival when compared to standard supportive care in higher risk patients as defined by the IPSS 151,152 .”
Influential
Myelodysplastic Syndromes
Tefferi, A., & Vardiman, J. W. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902908 · Cited by 685
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Malcovati, L., Hellström‐Lindberg, E., Bowen, D., Adès, L., Čermák, J., del Cañizo, C., Porta, M. G. D., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 682
Self-citation
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V. R., Bixby, D. L., Blum, W. G., Coutre, S. E., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0116 · Cited by 648
Self-citation
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., Ciceri, F., Blaser, J. G., Greystoke, B. F., Jordan, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.014 · Cited by 566
Acute myeloid leukaemia in adults
Ferrara, F., & Schiffer, C. A. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61727-9 · Cited by 573
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
Pei, S., Pollyea, D. A., Gustafson, A. L., Stevens, B. M., Minhajuddin, M., Fu, R., Riemondy, K. A., Gillen, A. E., Sheridan, R. M., Kim, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0710 · Cited by 565
“However, response to HMA therapy is limited and long-term overall survival is negligible (4,5).”
Background
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Bejar, R. L., Lord, A. M., Stevenson, K. E., Bar‐Natan, M., Pérez-Ladaga, A., Zaneveld, J. E., Wang, H., Caughey, B. A., Stojanov, P., Getz, G. A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582809 · Cited by 575
Epigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & Carvalho, D. D. D. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 559
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Lübbert, M., Suciu, S., Baila, L., Rüter, B. H., Platzbecker, U., Giagounidis, A. A. N., Selleslag, D., Labar, B., Germing, U., Salih, H. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.9245 · Cited by 557
Self-citation
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Aberrations of EZH2 in Cancer
Chase, A., & Cross, N. C. P. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2156 · Cited by 563
“the use of DNA demethylating agents azacytidine and decitabine for myelodysplastic syndrome (46, 47) and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (vorinostat) for cutaneous T-cell lymphoma (48).”
Background
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Itzykson, R., Kosmider, O., Renneville, A., Gelsi‐Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne‐Rauzy, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3314 · Cited by 559
Self-citation
IDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509
“Treatment of higher-risk MDS with azacitidine has shown improvement in median OS even in patients who did not achieve a CR [95, 96].”
Background
Myelodysplastic Syndromes
Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 508
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mufti, G. J., Mittelman, M., Muus, P., Boekhorst, P. A. W. T., Sanz, G. F., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 493
Self-citation
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., Dreyfus, F., Rauzy, O. B., Recher, C., Adès, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8135 · Cited by 475
“This raises interesting issues regarding possible effects of AZA, including, as suggested by others, a possible modification of the MDS natural history.(11,24) A variety of salvage regimens were administered to patients in the current cohort, although information regarding salvage treatment was missing for many of the…”
BackgroundResultSelf-citation
Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465
“PRD (63-97) DBD (102-292) TET (323-356) REG (363-393) TAD2 (43-62) TAD1 (1-42) CR mCR + HI mCR HI SD PD NR/NE”
Self-citation
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
Itzykson, R., Kosmider, O., Cluzeau, T., Mas, V. M., Dreyfus, F., Beyne‐Rauzy, O., Quesnel, B., Vey, N., Gelsi‐Boyer, V., Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 480
Self-citation
The mutational landscape of adenoid cystic carcinoma
Ho, A. S., Kannan, K. S., Roy, D. M., Morris, L. G. T., Ganly, I., Katabi, N., Ramaswami, D., Walsh, L. A., Eng, S., Huse, J. T., et al. (2013) · Nature Genetics · doi:10.1038/ng.2643 · Cited by 472
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Blum, W. G., Garzon, R., Klisovic, R. B., Schwind, S., Walker, A., Geyer, S. M., Liu, S., Havelange, V., Becker, H., Schaaf, L. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002650107 · Cited by 450
Self-citation
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Wei, A. H., Döhner, H., Pocock, C., Montesinos, P., Afanasyev, B. V., Dombret, H., Ravandi, F., Sayar, H., Jang, J., Porkka, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004444 · Cited by 450
Self-citation
Targeting DNA Methylation
Issa, J. J., & Kantarjian, H. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2783 · Cited by 463
“Finally, studies suggest that the quality of responses may be different with hypomethylators – survival in remission, for example, appears to be better with AZA and DAC compared to traditional chemotherapy[33,36].”
BackgroundMethodInfluential
Healthy Effects of Plant Polyphenols: Molecular Mechanisms
Leri, M., Scuto, M. C., Ontario, M. L., Calabrese, V., Calabrese, E. J., Bucciantini, M., & Stefani, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041250 · Cited by 460
“Finally, it appears that the inhibition of DNMT is a chemopreventive effect on cancer cell growth by genistein, suggesting its use as anti-neoplastic drug in some malignancies [272].”
Background
Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
de Lima, M., Giralt, S., Thall, P. F., Silva, L. D. P., Jones, R. B., Komanduri, K. V., Braun, T. M., Nguyen, H. Q., Champlin, R. E., & Garcia‐Manero, G. (2010) · Cancer · doi:10.1002/cncr.25500 · Cited by 427
“The median number of prior chemotherapy regimens was 2, 39 patients previously received high-dose Ara-C–based chemotherapy, and 18% of the patients had failed a previous allogeneic HSCT.”
BackgroundInfluential
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 424
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Berthon, C., Raffoux, E., Thomas, X., Vey, N., Gomez‐Roca, C., Yee, K. W. L., Taussig, D. C., Rezaï, K., Roumier, C., Herait, P., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00247-1 · Cited by 432
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Tallman, M. S., Wang, E. S., Altman, J. K., Appelbaum, F. R., Bhatt, V. R., Bixby, D. L., Coutre, S. E., Lima, M. J. G. D., Fathi, A. T., Fiorella, M., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0028 · Cited by 423
Cancer Epigenetics
Taby, R. F., & Issa, J. J. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20085 · Cited by 429
Myelodysplastic syndromes
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 418
Self-citation
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
Platzbecker, U., Wermke, M., Radke, J., Oelschlaegel, U., Seltmann, F., Kiani, A., Klut, I.-M., Knoth, H., Röllig, C., Schetelig, J., et al. (2011) · Leukemia · doi:10.1038/leu.2011.234 · Cited by 389
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D. W., Yakoub‐Agha, I., Mufti, G. J., Fenaux, P., Sanz, G. F., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 385
“Despite improved understanding of the molecular pathogenesis of myelodysplastic syndromes (MDS), currently available therapeutic agents lead to prolongation of life and no cure.(1) Therefore, allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used as a curative treatment option.”
BackgroundSelf-citation
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., Dartigeas, C., Legros, L., et al. (2010) · Blood · doi:10.1182/blood-2010-06-289280 · Cited by 381
“Patients received AZA for a median of 6 cycles (1-52).”
BackgroundSelf-citation
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Dawson, M. A. (2017) · Science · doi:10.1126/science.aam7304 · Cited by 377
A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Hollenbach, P. W., Nguyen, A. N., Brady, H. A., Williams, M. M., Ning, Y., Richard, N., Krushel, L. A., Aukerman, S. L., Heise, C. C., & MacBeth, K. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009001 · Cited by 362
“4 months) compared with conventional care regimens [14], DAC did not demonstrate a statistically significant improvement in survival in a similar clinical trial [15].”
Result
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 393
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
Platzbecker, U., Middeke, J. M., Sockel, K., Herbst, R., Wolf, D. G. F., Baldus, C. D., Oelschlägel, U., Mütherig, A., Fransecky, L. R., Noppeney, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30580-1 · Cited by 347
The genetic basis of myelodysplasia and its clinical relevance
Cazzola, M., Porta, M. G. D., & Malcovati, L. (2013) · Blood · doi:10.1182/blood-2013-09-381665 · Cited by 355
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Goodyear, O. C., Agathanggelou, A., Novitzky‐Basso, I., Siddique, S., McSkeane, T., Ryan, G. B., Vyas, P., Cavenagh, J. D., Stankovic, T., Moss, P. A. H., et al. (2010) · Blood · doi:10.1182/blood-2009-11-249474 · Cited by 340
Targeting DNA methylation for epigenetic therapy
Yang, X., Lay, F. D., Han, H., & Jones, P. A. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.001 · Cited by 333
“[102, 104] MDS Fenaux (2009) 358 17% CR, 12% PR, 42% SD Improved OS compared to CCR in high risk MDS patients (AZA-001).”
Background
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Figueroa, M. E., Skrabanek, L. A., Li, Y., Jiemjit, A., Fandy, T. E., Paietta, E. M., Fernandez, H. F., Tallman, M. S., Greally, J. M., Carraway, H. E., et al. (2009) · Blood · doi:10.1182/blood-2009-01-200519 · Cited by 325
Self-citation
β-Hydroxybutyrate suppresses colorectal cancer
Dmitrieva-Posocco, O., Wong, A. C., Lundgren, P., Golos, A., Descamps, H. C., Dohnalová, L., Cramer, Z., Tian, Y., Yueh, B., Eskiocak, O., et al. (2022) · Nature · doi:10.1038/s41586-022-04649-6 · Cited by 325
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Bejar, R. L., Levine, R. L., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 309
Concise Drug Review: Azacitidine and Decitabine
Derissen, E. J. B., Beijnen, J. H., & Schellens, J. H. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0465 · Cited by 299
“Themedian durationof thehematological responsewas about 13months in both azacitidine studies [2, 14, 15] and 9–10months in both decitabine studies [4, 5].”
BackgroundResultInfluential
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Greenberg, P. L., Stone, R. M., Al‐Kali, A., Barta, S. K., Bejar, R. L., Bennett, J. M., Carraway, H. E., de Castro, C. M., Deeg, H. J., Dezern, A. E., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0007 · Cited by 305
Self-citation
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
Pappalardi, M. B., Keenan, K., Cockerill, M. J., Kellner, W. A., Stowell, A. I. J., Sherk, C. S., Wong, K., Pathuri, S., Briand, J., Steidel, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00249-x · Cited by 290
Myelodysplastic Syndromes
Greenberg, P. L., Attar, E. C., Bennett, J. M., Bloomfield, C. D., Castro, C. M. D., Deeg, H. J., Foran, J. M., Gaensler, K. M. L., Garcia‐Manero, G., Gore, S. D., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0005 · Cited by 287
Self-citation
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
Pellagatti, A., Cazzola, M., Giagounidis, A. A. N., Perry, J., Malcovati, L., Porta, M. G. D., Jädersten, M., Killick, S. B., Verma, A. K., Norbury, C. J., et al. (2010) · Leukemia · doi:10.1038/leu.2010.31 · Cited by 279
Self-citation
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
Traina, F., Visconte, V., Elson, P. J., Tabarroki, A., Jankowska, A., Hasrouni, E., Sugimoto, Y., Szpurka, H., Makishima, H., O'Keefe, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.269 · Cited by 296
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
Koreth, J., Pidala, J., Pérez, W. S., Deeg, H. J., Garcia‐Manero, G., Malcovati, L., Cazzola, M., Park, S., Itzykson, R., Adès, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8652 · Cited by 287
Self-citation
Mechanisms of DNA–protein crosslink repair
Stingele, J., Bellelli, R., & Boulton, S. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.56 · Cited by 292
Eprenetapopt Plus Azacitidine in TP53 -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
Cluzeau, T., Sebert, M., Rahmé, R., Cuzzubbo, S., Lehmann-Che, J., Madelaine, I., Peterlin, P., Bève, B., Attalah, H., Chermat, F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02342 · Cited by 279
“TAD1 (1-42) TAD2 (43-62) PRD (63-97) DBD (102-292) TET (323-356) REG (363-393)”
Self-citation
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
Sasaki, K., Ravandi, F., Kadia, T. M., Dinardo, C. D., Short, N. J., Borthakur, G. M., Jabbour, E. J., & Kantarjian, H. M. (2021) · Cancer · doi:10.1002/cncr.33458 · Cited by 280
“1;q22), CBFB- MYH11”; “acute myeloid leukemia with minimal differentiation”; “acute myeloid leukemia without maturation”; “acute myeloid leukemia with maturation”; “acute monoblastic and monocytic leukemia”; “acute myeloid leukemia with myelodysplasia- related changes”; “acute myeloid leukemia, t(8;21)(q22;q22) RUNX1-…”
Background
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
Sallman, D. A., & List, A. (2019) · Blood · doi:10.1182/blood-2018-10-844654 · Cited by 273
The Role of DNA Methylation in Cancer
Lakshminarasimhan, R., & Liang, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43624-1_7 · Cited by 278
Diagnosis and Treatment of Myelodysplastic Syndromes
Sekeres, M. A., & Taylor, J. (2022) · JAMA · doi:10.1001/jama.2022.14578 · Cited by 267
TET proteins and the control of cytosine demethylation in cancer
Scourzic, L., Mouly, E., & Bernard, O. (2015) · Genome Medicine · doi:10.1186/s13073-015-0134-6 · Cited by 263
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Kröger, N. M., Iacobelli, S., Franke, G., Platzbecker, U., Uddin, R., Hübel, K., Scheid, C., Weber, T. E., Robin, M., Stelljes, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7349 · Cited by 250
Rational Therapeutic Combinations with Histone Deacetylase Inhibitors for the Treatment of Cancer
Thurn, K. T., Thomas, S., Moore, A. P., & Münster, P. N. (2011) · Future Oncology · doi:10.2217/fon.11.2 · Cited by 251
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Prébet, T., Sun, Z., Figueroa, M. E., Ketterling, R. P., Melnick, A. M., Greenberg, P. L., Herman, J. G., Juckett, M., Wang, E. S., Smith, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3102 · Cited by 247
Self-citation
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
Sekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2510 · Cited by 237
“99 SR 16 (15) 109 7,5,4 2(29),4(80),0(0) .”
Self-citation
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations
Will, B., Zhou, L., Vogler, T. O., Ben-Neriah, S., Schinke, C., Tamari, R., Yu, Y., Bhagat, T. D., Bhattacharyya, S., Barreyro, L., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399683 · Cited by 240
Self-citation
Treatment of MDS
Platzbecker, U. (2019) · Blood · doi:10.1182/blood-2018-10-844696 · Cited by 244
Epigenetics and cancer treatment
Kristensen, L. S., Nielsen, H. M., & Hansen, L. L. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.011 · Cited by 237
Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine
Liu, M., Ohtani, H., Zhou, W., Ørskov, A. D., Charlet, J., Zhang, Y. W., Shen, H., Baylin, S. B., Liang, G., Grønbæk, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612262113 · Cited by 225
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 236
“5-azacitidine has been studied in higher-risk MDS in two major randomized multicenter trials: CALGB 9221(136) and AZA-001.(86) In the CALGB 9221(136) study, 191 patients with MDS were randomized between 5-azacitidine (75 mg/m(2)/day for 7 consecutive days every 28 days) and best supportive care (BSC).”
BackgroundResultInfluential
Oncometabolites in renal cancer
Yong, C., Stewart, G. D., & Frezza, C. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0210-z · Cited by 215
Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
Tsirigotis, P. D., Byrne, M. T., Schmid, C., Baron, F., Ciceri, F., Esteve, J., Gorin, N. C., Giebel, S., Mohty, M., Savani, B. N., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.167 · Cited by 215
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
Litzow, M. R., Tarima, S. S., Pérez, W. S., Bolwell, B. J., Cairo, M. S., Camitta, B. M., Cutler, C. S., Lima, M. J. G. D., DiPersio, J. F., Gale, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-10-249128 · Cited by 213
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Garcia‐Manero, G., Griffiths, E. A., Steensma, D. P., Roboz, G. J., Wells, R. A., McCloskey, J. K., Odenike, O. M., Dezern, A. E., Yee, K. W. L., Busque, L., et al. (2020) · Blood · doi:10.1182/blood.2019004143 · Cited by 213
Germline DDX41 mutations define a significant entity within adult MDS/AML patients
Sébert, M., Passet, M., Raimbault, A., Rahmé, R., Raffoux, E., de Fontbrune, F. S., Cerrano, M., Quentin, S., Vasquez, N., Costa, M. D., et al. (2019) · Blood · doi:10.1182/blood.2019000909 · Cited by 212
Self-citation
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
Bravo, G. M., & Garcia‐Manero, G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 212
“Blum et al have indicated that a 10-day schedule of decitabine has significant activity in AML.120 Similar results have been reported by other groups in recent years.18 5-azacitidine has been studied in higher-risk MDS in two major randomized multicenter trials: CALGB 9221121 and AZA-001.”
BackgroundMethod
Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples
Iwamoto, T., Niikura, N., Ogiya, R., Yasojima, H., Watanabe, K., Kanbayashi, C., Tsuneizumi, M., Matsui, A., Fujisawa, T., Iwasa, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50099-y · Cited by 210
Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
Damaj, G. L., Duhamel, A., Robin, M., Beguin, Y. P., Michallet, M., Mohty, M., Vigouroux, S., Bories, P., Garnier, A., Cheikh, J. E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3499 · Cited by 206
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine
Yu, J., Qin, B., Moyer, A. M., Nowsheen, S., Liu, T., Qin, S., Zhuang, Y., Liu, D., Lu, W., Kalari, K. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97924 · Cited by 203
“5-Aza-2 ′ -deoxycytidine (decitabine) is a demethylating agent that is approved by many international regulatory agencies, including the US FDA and the European Commission (EC), for treating hematological malignancies (8–10) and that has become a standard of care for patients with higher risk myelodysplastic syndrome…”
Influential
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Braun, T., Itzykson, R., Renneville, A., Renzis, B. D., Dreyfus, F., Laribi, K., Bouabdallah, K. K., Vey, N., Toma, A., Récher, C., et al. (2011) · Blood · doi:10.1182/blood-2011-05-352039 · Cited by 201
“Median platelet number, g/L (range) 81 (12-560)”
Self-citation
Therapeutic targeting of tumor suppressor genes
Morris, L. G. T., & Chan, T. A.-T. (2014) · Cancer · doi:10.1002/cncr.29140 · Cited by 209
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
Bogenberger, J. M., Kornblau, S. M., Pierceall, W. E., Lena, R. J., Chow, D. C., Shi, C.-X., Mantei, J., Ahmann, G. J., Gonzales, I. M., Choudhary, A. K., et al. (2014) · Leukemia · doi:10.1038/leu.2014.44 · Cited by 199
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults
Savona, M. R., Malcovati, L., Komrokji, R. S., Tiu, R. V., Mughal, T. I., Orazi, A., Kiladjian, J., Padron, E., Solary, É., Tibes, R., et al. (2015) · Blood · doi:10.1182/blood-2014-10-607341 · Cited by 199
Self-citation
Epigenetic activities of flavonoids in the prevention and treatment of cancer
Busch, C., Burkard, M., Leischner, C., Lauer, U. M., Frank, J., & Venturelli, S. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0095-z · Cited by 205
“The ribonucleoside azacitidine is an analogue of cytosine, which is important for DNA and RNA synthesis [55].”
Background
Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
Zeidan, A. M., Shallis, R. M., Wang, R., Davidoff, A. J., & Ma, X. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.09.001 · Cited by 205
Incidence, survival and prevalence of myeloid malignancies in Europe
Visser, O. J., Trama, A., Maynadié, M., Stiller, C. A., Marcos‐Gragera, R., Angelis, R. D., Mallone, S., Ţereanu, C., Allemani, C., Ricardi, U., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.024 · Cited by 203
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes
Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström‐Lindberg, E., Gattermann, N., Sanz, G. F., List, A. F., Gore, S. D., & Seymour, J. F. (2011) · Cancer · doi:10.1002/cncr.25774 · Cited by 194
“The international phase 3 trial AZA-001 established that the cytidine nucleoside analog azacitidine significantly prolonged median overall survival by >9 months and significantly delayed median time to AML transformation by >6 months compared with conventional care regimens.(3) Azacitidine was also associated with sig…”
MethodResultInfluentialSelf-citation
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies
Tiu, R. V., Gondek, L. P., O’Keefe, C. L., Elson, P. J., Huh, J., Mohamedali, A. M., Kulasekararaj, A. G., Advani, A. S., PAQUETTE, R. L., List, A. F., et al. (2011) · Blood · doi:10.1182/blood-2010-07-295857 · Cited by 197
Self-citation
Novel Oligoamine Analogues Inhibit Lysine-Specific Demethylase 1 and Induce Reexpression of Epigenetically Silenced Genes
Huang, Y., Stewart, T. M., Wu, Y., Baylin, S. B., Marton, L. J., Perkins, B. N., Jones, R. J., Woster, P. M., & Casero, R. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1293 · Cited by 193

Authors: Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S. D., Seymour, J. F., Bennett, J. M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C., & Silverman, L. R.
Affiliations: Université Sorbonne Paris Nord (FR)
King's College Hospital (GB)
Azienda Ospedaliero-Universitaria Careggi (IT)
University Hospital Schleswig-Holstein (DE)
Düsseldorf University Hospital (DE)
Hospital Universitari i Politècnic La Fe (ES)
Moffitt Cancer Center (US)
Johns Hopkins University (US)
Karolinska University Hospital (SE)
University of Rochester Medicine (US)
The Ohio State University (US)
Celgene (United States) (US)
Icahn School of Medicine at Mount Sinai (US)
Corresponding author: Fenaux, Pierre
ORCID: Fenaux, Pierre
Mufti, Ghulam J
Santini, Valeria
Finelli, Carlo
Giagounidis, Aristoteles
Sanz, Guillermo
List, Alan
Gore, Steven D
Seymour, John F
Bennett, John M
Byrd, John
Silverman, Lewis R
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2009-03
Volume: 10
Issue: 3
Pages: 223-232
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(09)70003-8
PMC: PMC4086808
OpenAlex: W2118771330
Cited by: 2,663
References: 45
Citations by year: 2026: 80 · 2025: 99 · 2024: 103 · 2023: 153 · 2022: 149 · 2021: 182 · 2020: 148 · 2019: 149 · 2018: 132 · 2017: 164 · 2016: 178 · 2015: 173 · 2014: 201 · 2013: 182 · 2012: 178
FWCI: 124.66
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Florence Research (University of Florence) (submittedVersion)
IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
Research Portal (King's College London) (submittedVersion)
Funders: Celgene
National Cancer Institute (K24CA111717)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords: azacitidine, myelodysplastic syndrome, high-risk myelodysplastic syndrome, overall survival, low-dose cytarabine, intensive chemotherapy, best supportive care, hypomethylating agents, treatment efficacy comparison, hematologic malignancies
MeSH terms: Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Azacitidine, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes, Proportional Hazards Models

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks